# SRPT catalysts: Sarepta Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/srpt/catalysts

> Sarepta Therapeutics, Inc. (SRPT) has 3 upcoming catalysts. The next is the Sarepta Therapeutics, Inc. PDUFA date, February 28, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for SRPT?

Sarepta Therapeutics, Inc. (SRPT) has 3 upcoming catalysts. The next is the Sarepta Therapeutics, Inc. PDUFA date, February 28, 2027. SEC Form 10-Q: "As of the date of this Quarterly Report, we anticipate a PDUFA target action date of February 28, 2027." [Calendar and source filings](https://sec-api.dev/companies/srpt/catalysts)

Source: SEC Form 10-Q, accession 0001193125-26-449721, https://www.sec.gov/Archives/edgar/data/873303/000119312526449721/srpt-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/srpt/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Sarepta Therapeutics, Inc. |
| Ticker | SRPT (Nasdaq) |
| SEC CIK | 873303 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/srpt |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 19, 2019 | [Vyondys 53 (golodirsen) complete response letter (CRL)](https://sec-api.dev/pdufa/golodirsen) | SRPT |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22211970_2019_Orig1s000OtherActionLtrs.pdf%22)) |
| May 12, 2023 | [Delandistrogene moxeparvovec with the requested indication FDA advisory committee meeting](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec-with-the-requested-indication) | SRPT |  | completed | "On May 12, 2023, the committee will meet in open session to discuss the Biologics License Application (BLA) 125781 from Sarepta Therapeutics, Inc. for delandistrogene moxeparvovec with the requested indication for the treatment of ambulatory patients with Duchenne Muscular Dystrophy (DMD) with a confirmed mutation in the DMD gene." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-may-12-2023-meeting-announcement-05122023)) |
| January 13, 2025 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta will report its final and complete fourth quarter and full -year 2024 financial results in late February 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312525005160/d900352dex991.htm)) |
| February 26, 2025 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000095017025027717/srpt-ex99_1.htm)) |
| 2H 2025 | [Bidridistrogene xeboparvovec NDA/BLA submission](https://sec-api.dev/pdufa/bidridistrogene-xeboparvovec) | SRPT |  | scheduled | "Sarepta expects to submit the Biologics License Application for SRP-9003 for LGMD type 2E/R4 in the second half of this year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000095017025096257/srpt-ex99_1.htm)) |
| July 14, 2025 | [ELEVIDYS (delandistrogene moxeparvovec) earnings report](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec) | SRPT |  | completed | "In addition to the restructuring plan, the Company provided an update on activities related to the label updates underway for ELEVIDYS (delandistrogene moxeparvovec), the first and only approved gene therapy for the treatment of Duchenne muscular dystrophy and reported preliminary financial results for the quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000095017025096257/srpt-ex99_1.htm)) |
| November 3, 2025 | [Sarepta Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed, missed | "For example, on November 3, 2025, we announced topline results from our ESSENCE trial, a confirmatory trial intended to verify the clinical benefits of VYONDYS 53 and AMONDYS 45, which primary endpoint did not meet statistical significance." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/873303/000119312526449721/srpt-20260930.htm)) |
| November 3, 2025 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312525262591/srpt-ex99_1.htm)) |
| Jan 2026 | [ELEVIDYS (delandistrogene moxeparvovec) topline data readout](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec) | SRPT |  | completed, positive | "Announced positive three-year results from the EMBARK study: In January 2026, Sarepta reported topline three-year data from Part 1 of EMBARK (Study SRP-9001-301), the global, randomized, Phase 3 trial evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl), the first and only approved gene therapy for Duchenne muscular dystrophy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312526071566/srpt-ex99_1.htm)) |
| Q1 2026 | [SRP-1001 interim data readout](https://sec-api.dev/pdufa/srp-1001) | SRPT |  | scheduled | "We expect to share initial data in the first quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm)) |
| Q1 2026 | [SRP-1003 interim data readout](https://sec-api.dev/pdufa/srp-1003) | SRPT |  | scheduled | "We expect to share initial data in the first quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm)) |
| January 12, 2026 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta will report its final and complete fourth quarter and full-year 2025 financial results in late February 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312526010116/srpt-ex99_1.htm)) |
| February 25, 2026 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312526071566/srpt-ex99_1.htm)) |
| Q2 2026 | [SRP-1005 trial start](https://sec-api.dev/pdufa/srp-1005) | SRPT |  | scheduled | "Approval of CTA for SRP-1005 in Huntington's: In January 2026, Sarepta announced approval to begin a first-in-human Phase 1 trial of SRP-1005, an siRNA therapeutic for Huntington's disease, which will assess safety and tolerability in about 24 participants starting in Q2 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312526071566/srpt-ex99_1.htm)) |
| May 6, 2026 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312526208966/srpt-ex99_1.htm)) |
| August 5, 2026 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312526335056/srpt-ex99_1.htm)) |
| September 7, 2026 | [Eteplirsen primary completion](https://sec-api.dev/pdufa/eteplirsen) | SRPT | Muscular Dystrophy, Duchenne | completed | "NCT03992430 (A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-07 (ACTUAL); Lead Sponsor Sarepta Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03992430)) |
| Sep to Dec 2026 | [Eteplirsen topline data readout](https://sec-api.dev/pdufa/eteplirsen) | SRPT | Muscular Dystrophy, Duchenne | scheduled | "NCT03992430 (A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-07 (ACTUAL); Lead Sponsor Sarepta Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03992430)) |
| November 5, 2026 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312526449822/srpt-ex99_1.htm)) |
| February 28, 2027 | [Sarepta Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | scheduled | "As of the date of this Quarterly Report, we anticipate a PDUFA target action date of February 28, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/873303/000119312526449721/srpt-20260930.htm)) |
| May to Aug 2027 | [ELEVIDYS (delandistrogene moxeparvovec) topline data readout](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec) | SRPT | Duchenne Muscular Dystrophy | scheduled | "NCT05881408 (A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Sarepta Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05881408)) |
| May 2027 | [ELEVIDYS (delandistrogene moxeparvovec) primary completion](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec) | SRPT | Duchenne Muscular Dystrophy | scheduled | "NCT05881408 (A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Sarepta Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05881408)) |

## Drugs

- [Bidridistrogene xeboparvovec](https://sec-api.dev/pdufa/bidridistrogene-xeboparvovec): 
- [ELEVIDYS (delandistrogene moxeparvovec)](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec): Duchenne Muscular Dystrophy
- [Delandistrogene moxeparvovec with the requested indication](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec-with-the-requested-indication): 
- [Eteplirsen](https://sec-api.dev/pdufa/eteplirsen): Muscular Dystrophy, Duchenne
- [Vyondys 53 (golodirsen)](https://sec-api.dev/pdufa/golodirsen): 
- [SRP-1001](https://sec-api.dev/pdufa/srp-1001): 
- [SRP-1003](https://sec-api.dev/pdufa/srp-1003): 
- [SRP-1005](https://sec-api.dev/pdufa/srp-1005): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/srpt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SRPT catalysts: Sarepta Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/srpt/catalysts

```bibtex
@misc{secapidev_companies_srpt_catalysts_20261116,
  title        = {SRPT catalysts: Sarepta Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/srpt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_srpt_catalysts_20261116","title":"SRPT catalysts: Sarepta Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/srpt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
